Mycenax and RIN Sign License Agreement
Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, announced the signing of a License Agreement with Japan-based RIN Institute Inc.
The agreement grants Mycenax rights to apply RIN's proprietary Val-Leu-Lys (VLK) linker technology in CDMO services worldwide.
RIN's VLK linker has demonstrated superior anti-tumor efficacy and high serum stability, enabling the development of advanced ADCs.
- The VLK linker facilitates cytotoxicity through two mechanisms: action within the tumor microenvironment and enhanced ADC internalization.
The agreement strengthens Mycenax's capability to deliver differentiated ADC solutions for global pharmaceutical partners.
Author summary: Mycenax partners with RIN to advance ADC development.
More News
- Executive Turntable: RCA UK’s Stacey Tang to Lead BRIT Awards 2026 — Plus, Five New Veeps at BMG
- 10 tracks that prove MF DOOM was the master of samples
- Firefighters Ordered To Abandon Smoldering Site Days Before Catastrophic Palisades Fire Exploded
- Two Killed After Wrong-Way BMW Driver Crashes Into Cybertruck | Carscoops
- Friday Music Guide: New Music From Florence + The Machine, Tyler, The Creator, Brent Faiyaz & More
- Taylor Swift Drops Hushed ‘Alone In My Tower’ Acoustic Version of ‘The Fate of Ophelia’
- Sean Combs Transferred to Federal Prison in New Jersey to Begin Serving Four-Year Sentence
- Will AI ‘Fundamentally Change’ Working In Live Music?
- JD Vance and Erika Kirk’s on-stage hug goes viral amid faith and controversy debate | The Express Tribune
- WME’s Kirk Sommer Named MUSEXPO’s ‘International Music Person of the Year’